Dublin, Ohio-based Cardinal Health, Inc. (CAH) manufactures and distributes pharmaceuticals, medical & laboratory products, ...

The board of Cardinal Health, Inc. ( NYSE:CAH ) has announced that it will pay a dividend on the 15th of April, ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Fintel reports that on February 5, 2025, Jefferies upgraded their outlook for Cardinal Health (NYSE:CAH) from Hold to Buy.

Jefferies has upgraded Cardinal Health (CAH) to buy from hold, citing management's emerging EPS track record. Read more here.

Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock ...

Jefferies analyst Brian Tanquilut upgraded Cardinal Health (CAH) to Buy from Hold with a price target of $150, up from $140. The firm thinks ...

Healthcare distributor and services company Cardinal Health (NYSE:CAH) beat Wall Street’s revenue expectations in Q4 CY2024, ...

Cardinal Health, Inc. CAH reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.93, which beat the Zacks Consensus Estimate of $1.75 by 10.3%. The bottom line also improved 2 ...